Key Personal Information to Tell Your Doctor Before Starting Alectinib (Alecensa)

Key Personal Information to Tell Your Doctor Before Starting Alectinib (Alecensa)

Before initiating treatment with alectinib, patients must fully disclose their health status to their physician to ensure medication safety. In particular, mention whether you have any liver disease (e.g., hepatitis, cirrhosis), chronic lung disease or respiratory impairment, baseline bradycardia, or any cardiac conduction abnormalities. In addition, fertility-related issues are critical: ALECENSA can cause fetal harm, so women of childbearing potential must have a negative pregnancy test before starting treatment, and must use highly effective contraception during treatment and for at least 5 weeks after the last dose; if pregnancy occurs or is suspected during treatment, notify your doctor immediately. Male patients with female partners of childbearing potential should also use effective contraception during treatment and for at least 3 months after stopping the drug. For nursing mothers, it is unknown whether alectinib passes into breast milk, so it is recommended to avoid breastfeeding during treatment and for 1 week after the last dose. At the same time, patients should list all medications they are taking (including prescription drugs, over‑the‑counter medicines, vitamins, and herbal products) to avoid potential drug interactions.

How Effective Is Alectinib (Alecensa) as Adjuvant Therapy?

The efficacy of alectinib as postoperative adjuvant therapy was validated in a Phase III clinical study called ALINA. This trial enrolled 257 patients with stage IB to IIIA ALK‑positive NSCLC, all of whom had undergone complete surgical resection of the tumor and were then randomly assigned to receive alectinib or standard platinum‑based chemotherapy. The primary efficacy endpoint was disease‑free survival (DFS), defined as the time from randomization to recurrence or death. Results showed that the alectinib group had a 76% reduction in the risk of recurrence or death compared with the chemotherapy group (hazard ratio 0.24), a reduction that was statistically significant. At the 2‑year landmark analysis, the proportion of patients free from recurrence was 94% in the alectinib group versus 64% in the chemotherapy group. Even more impressive, the incidence of central nervous system (brain) recurrence was reduced by 78% with alectinib versus chemotherapy; only 3% of patients in the alectinib group had brain metastasis at recurrence, compared with 11% in the chemotherapy group. These data support the superiority of alectinib in the adjuvant setting, but note that the 2‑year results are descriptive analyses, and individual benefit may vary. Patients should discuss the interpretation of these results in depth with their doctor.

Storage and Missed‑Dose Management for Alectinib (Alecensa)

Proper storage and dosing habits directly affect the efficacy and safety of alectinib. The medication should be kept in its original manufacturer packaging, stored in a dry, light‑protected environment, and at a temperature not exceeding 30°C (86°F), avoiding heat or moisture. If you suspect the drug has been exposed to extreme temperatures (e.g., high heat inside a car in summer), contact your pharmacy for advice. During treatment, if a dose is missed, do not take a double dose; simply take the next scheduled dose at the regular time. If vomiting occurs immediately after taking the dose, do not retake the dose—wait for the next scheduled time. These rules are designed to avoid excessively high blood concentrations from extra dosing. In addition, ALECENSA is usually dispensed through specialty pharmacies; patients should ensure they answer and return calls from the pharmacy to avoid delays in medication delivery. If you are unable to receive home delivery, you may authorize the pharmacy to send the drug to a nearby retail pharmacy for pickup. If you encounter any uncertain situations during treatment, contact your healthcare team at any time—do not manage it on your own.